Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 501

1.

The value of serum alpha-fetoprotein in predicting tumor recurrence after liver transplantation for hepatocellular carcinoma.

Xu X, Ke QH, Shao ZX, Wu J, Chen J, Zhou L, Zheng SS.

Dig Dis Sci. 2009 Feb;54(2):385-8. doi: 10.1007/s10620-008-0349-0. Epub 2008 Jun 18.

PMID:
18563566
2.

The role of (18)F-FDG-PET imaging for the selection of liver transplantation candidates among hepatocellular carcinoma patients.

Yang SH, Suh KS, Lee HW, Cho EH, Cho JY, Cho YB, Yi NJ, Lee KU.

Liver Transpl. 2006 Nov;12(11):1655-60. Erratum in: Liver Transpl. 2007 Jan;13(1):175.

3.

[Prognostic factors of hepatocellular carcinoma after liver transplantation].

Zhou LX, Yan LN.

Ai Zheng. 2006 Jun;25(6):736-9. Chinese.

PMID:
16764771
4.
5.

Progression of alphafetoprotein before liver transplantation for hepatocellular carcinoma in cirrhotic patients: a critical factor.

Vibert E, Azoulay D, Hoti E, Iacopinelli S, Samuel D, Salloum C, Lemoine A, Bismuth H, Castaing D, Adam R.

Am J Transplant. 2010 Jan;10(1):129-37. doi: 10.1111/j.1600-6143.2009.02750.x.

6.

Primary hepatocellular cancer in the explanted liver: outcome of transplantation and risk factors for HCC recurrence.

Kondili LA, Lala A, Gunson B, Hubscher S, Olliff S, Elias E, Bramhall S, Mutimer D.

Eur J Surg Oncol. 2007 Sep;33(7):868-73. Epub 2007 Jan 26.

PMID:
17258882
7.

Liver transplantation for hepatocellular carcinoma and cirrhosis in candidates with undetectable or very low alpha-fetoprotein levels: is an expansion of the listing criteria justified?

Sotiropoulos GC, Malagó M, Bockhorn M, Schmitz KJ, Radtke A, Molmenti EP, Schaffer R, Beckebaum S, Cicinnati VR, Fouzas I, Broelsch CE, Lang H.

Hepatogastroenterology. 2008 Sep-Oct;55(86-87):1671-7.

PMID:
19102367
8.

Detection of AFP mRNA-expressing cells in the peripheral blood for prediction of HCC recurrence after living donor liver transplantation.

Marubashi S, Dono K, Nagano H, Sugita Y, Asaoka T, Hama N, Miyamoto A, Takeda Y, Umeshita K, Monden M.

Transpl Int. 2007 Jul;20(7):576-82. Epub 2007 Apr 8.

9.

Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence.

Vivarelli M, Cucchetti A, La Barba G, Ravaioli M, Del Gaudio M, Lauro A, Grazi GL, Pinna AD.

Ann Surg. 2008 Nov;248(5):857-62. doi: 10.1097/SLA.0b013e3181896278.

PMID:
18948815
10.

Liver transplantation for hepatocellular carcinoma: Hangzhou experiences.

Zheng SS, Xu X, Wu J, Chen J, Wang WL, Zhang M, Liang TB, Wu LM.

Transplantation. 2008 Jun 27;85(12):1726-32. doi: 10.1097/TP.0b013e31816b67e4.

PMID:
18580463
11.

HCC in living donor liver transplantation: can we expand the Milan criteria?

Kwon CH, Kim DJ, Han YS, Park JB, Choi GS, Kim SJ, Joh JW, Lee SK.

Dig Dis. 2007;25(4):313-9.

PMID:
17960066
12.

A revised scoring system utilizing serum alphafetoprotein levels to expand candidates for living donor transplantation in hepatocellular carcinoma.

Yang SH, Suh KS, Lee HW, Cho EH, Cho JY, Cho YB, Kim IH, Yi NJ, Lee KU.

Surgery. 2007 May;141(5):598-609. Epub 2007 Mar 23.

PMID:
17462459
13.

[Correlation of perioperative alpha-fetoprotein expression in peripheral blood to recurrence of hepatocellular carcinoma].

Shi M, Zhang Y, Zhong C, Lin XJ, Zhang CQ, Li JQ.

Ai Zheng. 2008 Jan;27(1):83-7. Chinese.

PMID:
18184471
14.

Liver transplantation for patients with hepatocellular carcinoma.

Ho MC, Wu YM, Hu RH, Ko WJ, Yang PM, Lai MY, Lin MH, Lin HY, Lee PH.

Transplant Proc. 2004 Oct;36(8):2291-2.

PMID:
15561223
15.

Locoregional recurrences are frequent after radiofrequency ablation for hepatocellular carcinoma.

Harrison LE, Koneru B, Baramipour P, Fisher A, Barone A, Wilson D, Dela Torre A, Cho KC, Contractor D, Korogodsky M.

J Am Coll Surg. 2003 Nov;197(5):759-64.

PMID:
14585410
16.
17.

An analysis of the UNOS liver transplant registry: high serum alpha-fetoprotein does not justify an increase in MELD points for suspected hepatocellular carcinoma.

Kemmer N, Neff G, Kaiser T, Zacharias V, Thomas M, Tevar A, Satwah S, Shukla R, Buell J.

Liver Transpl. 2006 Oct;12(10):1519-22.

18.

Combination of morphologic criteria and α-fetoprotein in selection of patients with hepatocellular carcinoma for liver transplantation minimizes the problem of posttransplant tumor recurrence.

Grąt M, Kornasiewicz O, Lewandowski Z, Hołówko W, Grąt K, Kobryń K, Patkowski W, Zieniewicz K, Krawczyk M.

World J Surg. 2014 Oct;38(10):2698-707. doi: 10.1007/s00268-014-2647-3.

19.

Prospective histopathological analysis of hepatocellular carcinoma treated with percutaneous ethanol injection in patients on the waiting list for liver transplantation.

Castroagudin JF, Delgado M, Martinez SM, Abdulkader I, Potel J, Tome S, Otero E, Varo E.

Transplant Proc. 2005 Apr;37(3):1477-9.

PMID:
15866645
20.

Association between recurrence of hepatocellular carcinoma and alpha-fetoprotein messenger RNA levels in peripheral blood.

Morimoto O, Nagano H, Miyamoto A, Fujiwara Y, Kondo M, Yamamoto T, Ota H, Nakamura M, Wada H, Damdinsuren B, Marubashi S, Dono K, Umeshita K, Nakamori S, Sakon M, Monden M.

Surg Today. 2005;35(12):1033-41.

PMID:
16341483
Items per page

Supplemental Content

Write to the Help Desk